Product sales for the vaccine specialist Valneva reached €170m despite slow US sales of its chikungunya vaccine.

Two years on, Bavarian Nordic’s $380 million vaccine M&A move appears to be paying off. | Valneva may have won the ...

Valneva SE (“Valneva”) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) ...

Bavarian Nordic sets up a bout with Valneva’s Ixchiq, the former’s Vimkunya already having an edge in population reach.

1 Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® - Valneva 2 Valneva Announces U.S. FDA Approval of World's First Chikungunya ...

approved the vaccine chikungunya vaccine (live) (brand name IXCHIQ) to protect adults against chikungunya disease, caused by the chikungunya virus (CHIKV). CHIKV is found in the subtropical regions of ...

Infected mosquitoes spread the chikungunya virus through their bites. The main transmitters are the Aedes aegypti and Aedes albopictus species. The same 2 species of mosquitoes also transmit dengue.

Colombo, February 4 (Daily Mirror) - Sri Lanka is experiencing a rise in Chikungunya cases, with the highest number of infections being reported across the country. Paediatrician at Lady Ridgeway ...

Furthermore, approximately DKK 2,500 million from Travel Health vaccines, and approximately DKK 200 million from contract work are expected. Travel Health revenue includes DKK 50 - 100 million from ...

Under the terms of Valneva's one-year contract, the U.S. will purchase a minimum of $32.8 million worth of the vaccine, with the option to buy additional doses over the next 12 months. Deliveries ...